1. Home
  2. SMWB vs VTYX Comparison

SMWB vs VTYX Comparison

Compare SMWB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Similarweb Ltd.

SMWB

Similarweb Ltd.

HOLD

Current Price

$7.27

Market Cap

747.7M

Sector

Technology

ML Signal

HOLD

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$7.39

Market Cap

713.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMWB
VTYX
Founded
2007
2018
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
747.7M
713.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SMWB
VTYX
Price
$7.27
$7.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$14.38
$14.60
AVG Volume (30 Days)
317.5K
1.4M
Earning Date
02-10-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$275,429,000.00
N/A
Revenue This Year
$16.89
N/A
Revenue Next Year
$13.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.25
N/A
52 Week Low
$6.36
$0.78
52 Week High
$17.64
$10.55

Technical Indicators

Market Signals
Indicator
SMWB
VTYX
Relative Strength Index (RSI) 46.39 46.58
Support Level $6.97 $8.61
Resistance Level $7.70 $9.30
Average True Range (ATR) 0.32 0.64
MACD 0.04 -0.10
Stochastic Oscillator 49.42 46.94

Price Performance

Historical Comparison
SMWB
VTYX

About SMWB Similarweb Ltd.

Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: